Results of the randomized National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) trial on women aged ≥60 years, who had received definitive surgery for hormone receptor-positive BC and ET, reported significantly worse diarrhea and headache in the AI group compared with the Tam group.20 The NSAS BC 04 trial that includes a smaller number of patients (n = 166) compared Tamoxifen to exemestane and reported that the FACT-B scores improved after treatment began and remained significantly higher in the tamoxifen group than in the exemestane or anastrozole groups for 1 year (p = 0.045). The gene discussed is NR4A1; the disease is breast carcinoma.